Chembio Diagnostics Inc (NASDAQ:CEMI) CFO Neil A. Goldman acquired 14,815 shares of the company’s stock in a transaction that occurred on Tuesday, February 13th. The shares were acquired at an average cost of $6.75 per share, with a total value of $100,001.25. Following the purchase, the chief financial officer now directly owns 14,815 shares of the company’s stock, valued at approximately $100,001.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Chembio Diagnostics Inc (NASDAQ:CEMI) traded up $0.20 during trading hours on Tuesday, reaching $7.40. The company had a trading volume of 144,400 shares, compared to its average volume of 30,288. The company has a market capitalization of $88.70, a price-to-earnings ratio of -12.98 and a beta of 1.14. Chembio Diagnostics Inc has a 12 month low of $5.05 and a 12 month high of $9.20. The company has a quick ratio of 2.19, a current ratio of 3.54 and a debt-to-equity ratio of 0.01.

A number of large investors have recently bought and sold shares of CEMI. Goldman Sachs Group Inc. bought a new stake in Chembio Diagnostics during the second quarter valued at $151,000. Benchmark Capital Advisors boosted its stake in Chembio Diagnostics by 174.2% during the third quarter. Benchmark Capital Advisors now owns 32,900 shares of the company’s stock valued at $204,000 after buying an additional 20,900 shares during the period. Wells Fargo & Company MN boosted its stake in Chembio Diagnostics by 55.4% during the second quarter. Wells Fargo & Company MN now owns 74,186 shares of the company’s stock valued at $449,000 after buying an additional 26,436 shares during the period. Finally, Royce & Associates LP boosted its stake in Chembio Diagnostics by 367.6% during the fourth quarter. Royce & Associates LP now owns 102,400 shares of the company’s stock valued at $840,000 after buying an additional 80,500 shares during the period. 34.00% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Insider Buying: Chembio Diagnostics Inc (CEMI) CFO Buys 14,815 Shares of Stock” was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://theolympiareport.com/2018/02/13/insider-buying-chembio-diagnostics-inc-cemi-cfo-buys-14815-shares-of-stock.html.

About Chembio Diagnostics

Chembio Diagnostics, Inc (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc, develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company’s products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies.

Receive News & Ratings for Chembio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chembio Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.